Dr John Dixon
Drug Discovery Advisor & member of Sentinel Board of Directors
John has over 40 years’ experience in Pharmaceutical Research & Development. John was head of Medicinal Chemistry for 20 years at Fisons, Vice President of Pre-Clinical R&D at Astra Charnwood for 4 years and Vice President of Drug Discovery at AstraZeneca Charnwood for 9 years. As VP of AstraZeneca Charnwood he delivered 35 candidate drugs. John retired from AstraZeneca in July 2008 becoming Director of JD International Consulting Ltd, an independent consultancy in Drug Discovery and Development.
Up to the present time he has advised over 120 clients from all sectors of the industry as well as academic, charities and government agencies in 12 different countries in all therapeutic areas. He became a drug discovery advisor to Sentinel Oncology in 2008 and a board member shortly afterwards. John is a Fellow of the Royal Society of Chemistry and Member of the American Chemical Society and has served on several professional and academic advisory committees. In 2004, John was awarded an honorary D.Sc. from Loughborough University in the UK for meritorious service to Medical Science and the community.
